Zhan, F., Barlogie, B., Mulligan, G., Shaughnessy, J. D., & Bryant, B. (2008). High-risk myeloma: A gene expression–based risk-stratification model for newly diagnosed multiple myeloma treated with high-dose therapy is predictive of outcome in relapsed disease treated with single-agent bortezomib or high-dose dexamethasone. American Society of Hematology.

Zhan, Fenghuang, Bart Barlogie, George Mulligan, John D. Shaughnessy, و Barb Bryant. High-risk Myeloma: A Gene Expression–based Risk-stratification Model for Newly Diagnosed Multiple Myeloma Treated With High-dose Therapy Is Predictive of Outcome in Relapsed Disease Treated With Single-agent Bortezomib or High-dose Dexamethasone. American Society of Hematology, 2008.

Zhan, Fenghuang, et al. High-risk Myeloma: A Gene Expression–based Risk-stratification Model for Newly Diagnosed Multiple Myeloma Treated With High-dose Therapy Is Predictive of Outcome in Relapsed Disease Treated With Single-agent Bortezomib or High-dose Dexamethasone. American Society of Hematology, 2008.